

Correction

Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

Trevor Powles¹, Alexander Paterson², Eugene McCloskey³, Phil Schein⁴, Bobbi Scheffler⁵, Alwynne Tidy⁶, Sue Ashley⁶, Ian Smith⁶, Lars Ottestad⁷ and John Kanis³

¹Parkside Oncology, London, UK

²Tom Baker Cancer Centre, Calgary, Alberta, Canada

³WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK

⁴Department of Clinical Pharmacology, University of Oxford, Oxford, UK

⁵Scheffler Group, Villanova, Pennsylvania, USA

⁶Royal Marsden Hospital, London, UK

⁷Radium Institute, Oslo, Norway

Corresponding author: Trevor Powles, hdummer@parkside-hospital.co.uk

Published: 3 May 2006

This article is online at <http://breast-cancer-research.com/content/8/3/406>

© 2006 BioMed Central Ltd

Breast Cancer Research 2006, **8**:406 (doi:10.1186/bcr1413)

It has been brought to our attention that there was a typographical error in our recent article [1] published in March 2006.

In the Conclusions section the final sentence should read:

Questions such as the optimal duration of therapy and efficacy in stage I disease remain to be answered.

References

1. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J: **Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]**. *Breast Cancer Research* 2006, **8**:R13.